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concise communication

Variability in Antifungal and Antiviral Use
in Hospitalized Children
Jennifer L. Goldman, MD, MS;1 Rachael K. Ross, MPH;2
Brian R. Lee, MPH, PhD;1 Jason G. Newland, MD, Med;3
Adam L. Hersh, MD, PhD;4 Matthew P. Kronman, MD,
MSCE;5 Jeffrey S. Gerber, MD, PhD2

We analyzed antifungal and antiviral prescribing among high-risk
children across freestanding children’s hospitals. Antifungal and antiviral days of therapy varied across hospitals. Benchmarking antifungal
and antiviral use and developing antimicrobial stewardship strategies to
optimize use of these high cost agents is needed.
Infect Control Hosp Epidemiol 2 0 17 ;3 8 :7 4 3– 7 46

Antimicrobial stewardship programs (ASPs) have primarily
focused on the optimization of antibiotic therapy, whereas the
use of antifungal therapy and antiviral therapy has been
relatively ignored.1 Antifungal and antiviral medications are
often used for both treatment and prophylaxis for high-risk
conditions like those in oncology and transplant patients.
Furthermore, these agents are frequently associated with
adverse drug effects, and they are costly. Hospitalized patients
receiving these agents demand closer scrutiny to improve
patient outcomes and potentially reduce hospital expenditures.2 The 2016 Infectious Diseases Society of America and
the Society for Healthcare Epidemiology of America ASP
guidelines recommend that stewardship should expand to
include antifungal therapy.3 Although prescribing trends of
antifungal and antiviral drugs among children are relatively
unknown, data suggest that their use is increasing.4 The
objectives of this study were (1) to characterize antifungal and
antiviral prescribing for hospitalized children including
comparison between high-risk and non–high-risk groups
and (2) to describe variability of antifungal and antiviral
prescribing among high-risk children to determine whether
there are potentially important pediatric stewardship targets.

m e th o d s
We performed a retrospective cohort study of antifungal and
antiviral prescribing in high risk hospitalized patients <18
years of age discharged between January 1 and December 31,
2015. Data were obtained from the Pediatric Health
Information System database, a clinical and administrative
database that contains inpatient demographic, diagnosis, and
prescribing charge data from 47 freestanding children’s
hospitals across the United States. We a priori identiﬁed

children considered to be at the highest risk for fungal or
viral infections, including those coded with an All Patient
Reﬁned Diagnosis Related Group (APR-DRG; version 32) for
oncology, bone marrow transplant, or solid organ transplant
(Table 1).
Antifungal therapy included ﬂuconazole, voriconazole,
posaconazole, itraconazole, amphotericin, caspofungin,
micafungin, anidulafungin, ﬂucytosine, or terbinaﬁne; antiviral therapy included charges for acyclovir, cidofovir, famciclovir, foscarnet, ganciclovir, oseltamivir, peramivir, ribavirin,
rimantadine, valacyclovir, valganciclovir, or zanamivir.
Data regarding age, race, gender, and receipt of any systemic
antifungal or antiviral therapy were collected. Total days of
antifungal or antiviral therapy (DOT) were standardized per
1,000 patient days. Summary statistics were constructed using
frequencies and proportions for categorical data and medians
and interquartile ranges (IQR) for continuous variables.
Analyses were performed with SAS version 9.4 software
(SAS Institute, Cary, NC) and Stata version 14.2 software
(StataCorp, College Station, TX). This study was not
considered human subject research by the Children’s Hospital
of Philadelphia Institutional Review Board.

resul ts
In 2015, there were 784,240 inpatient discharges from the
47 hospitals included in our analysis; 35,211 (4.5%) of these
patients were classiﬁed as oncology, bone marrow transplant,
or solid organ transplant by APR-DRG. These high-risk
patients were predominately male (56%) and Caucasian
(63%), with a median age of 7.9 years (interquartile range
[IQR], 3.6–13.6). Among this high-risk cohort, chemotherapy
was the most common APR-DRG (54%), followed by major
hematologic/immunologic diagnosis (21%), acute leukemia
(7%), and bone marrow transplant (4%). Solid organ transplants including heart, lung, liver, and kidney accounted for
approximately 3% of the total high-risk population.
Across all hospitalized patients, only 3% received antifungal
or antiviral therapy. In comparison, among the high-risk
patients, 19% received antifungal therapy and 12% received
antiviral therapy. These high-risk patients received 50% of all
antifungal DOT and 46% of all antiviral DOT despite
comprising <5% of all hospital discharges. Overall, high-risk
patients received 10 times more DOT than non–high-risk
patients: 389 antifungal DOT per 1,000 patient days versus
30 DOT, and 244 antiviral DOT per 1,000 patient days versus
22 DOT, respectively.
The highest percentage of prescribed antifungals (% total
DOT) occurred in patients hospitalized for bone marrow transplant (20%), chemotherapy (10.5%), and acute leukemia (6.5%).
The highest percentage of prescribed antiviral (% total DOT)
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Antifungal and Antiviral Therapy Prescribing Among High-Risk Children in 47 Freestanding Children’s Hospitals
Antifungal Therapy

All Patient Reﬁned Diagnosis Related Group Title
Chemotherapy
Major hematologic/immunologic diagnosis except
sickle cell crisis & coagulopathy
Acute leukemia
Bone marrow transplant
Nervous system malignancy
Other or prophylaxis for lymphatic/hematopoietic/
other neoplasms
Musculoskeletal malignancy & related pathological
fractures
Lymphoma, myeloma & nonacute leukemia
Major or prophylaxis for lymphatic/hematopoietic/
other neoplasms
Kidney transplant
Heart &/or lung transplant
Kidney & urinary tract procedures for malignancy
Liver transplant &/or intestinal transplant
Radiotherapy
Lymphatic & other malignancies & neoplasms of
uncertain behavior
Malignancy of hepatobiliary system & pancreas
Kidney & urinary tract malignancy
Ear, nose, mouth, throat, cranial/facial malignancies
Respiratory malignancy
Digestive malignancy
Uterine & adnexa procedures for ovarian & adnexal
malignancy
Female reproductive system malignancy
Malignancy, male reproductive system
Uterine & adnexa prophylaxis for nonovarian &
nonadnexal malignancy
NOTE.

Total
Patients
Patients Prescribed, %

Antiviral Therapy

DOT per
1,000 days

Patients
Prescribed, %

DOT per
1,000 days

18,884
7,474

12
20

257
306

5
11

70
148

2,431
1,323
772
500

34
93
6
19

460
845
66
434

11
80
3
7

100
685
25
92

488

4

36

4

45

459
434

19
26

279
443

10
6

80
94

363
362
336
332
274
264

21
41
4
71
2
10

116
125
41
459
101
131

88
83
0
94
1
5

656
308
0
626
31
62

115
100
93
78
44
39

9
4
9
6
16
0

151
30
110
55
233
0

3
1
2
8
9
0

11
5
23
36
141
0

26
15
5

15
0
40

250
0
159

4
7
0

73
34
0

DOT, days of therapy.

was used for children hospitalized for bone marrow transplant
(24.1%), heart and/or lung transplant (4.8%), and liver and/or
intestinal transplant (4.2%). Children hospitalized with a bone
marrow transplant were prescribed 845 DOT per 1,000 patient
days of antifungal therapy (range, 664–1194) and 685 DOT per
1,000 patient days of antiviral therapy (range, 358–1,048)
(Table 1).
Examination by drug class revealed total DOT rates
among high-risk patients as follows: ﬂuconazole, 135 DOT per
1,000 patient days; echinocandins, 127 DOT per 1,000 patient
days; voriconazole, 84 DOT per 1,000 patient days; and
amphotericin, 24 DOT per 1,000 patient days. Antiviral drugs
targeting herpes viruses (ie, acyclovir, cidofovir, famciclovir,
foscarnet, ganciclovir, ribavirin, valacyclovir, or valganciclovir)
were prescribed 241 DOT per 1,000 patient days. The prevalence
and total use of antifungal and antiviral therapy among high-risk
patients varied widely across hospitals (Figure 1): antifungal use

ranged from 75 to 608 DOT per 1,000 patient days and antiviral
use ranged from 18 to 451 DOT per 1,000 patient days across
centers. The correlation between AFT and AVT DOT rates
across hospitals was 0.58 (P < .001).

d is c u s s i o n
We examined antifungal and antiviral use among a high-risk
pediatric population admitted to 47 children’s hospitals. Our
results revealed (1) that this immune-compromised population accounts for most antifungal and antiviral prescribing in
hospitals and (2) that variability in the use of these agents
exists, even when examining this relatively homogenous
cohort.
Variability in antimicrobial exposure has been observed in
high-risk pediatric patients, though previous work has focused
on antibacterial therapy.5 Antifungal and antiviral agents
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ﬁgure 1. Variability in antifungal and antiviral therapy prescribing among high-risk children in 47 freestanding children’s hospitals.
Panel A: antifungal therapy. Panel B: antiviral therapy. Gray bars: left y-axis depicts DOT per 1,000 patient days. Black dots: right y-axis
depicts percentage of patients who were prescribed therapy. DOT, days of therapy.

represent important stewardship targets because they (1) are
often used for the treatment or prevention of relatively
high-risk infections, (2) can be associated with a relatively high
rate of adverse drug effects, (3) often require challenging
therapeutic drug monitoring, and (4) are disproportionately
costly relative to utilization.2,6,7 Although guidelines have been
developed to address antifungal and antiviral therapy in
oncology and transplant patients,8,9 our data demonstrate
that prescribing variability exists and more can be done to
standardize practice and minimize unnecessary use.
Antimicrobial stewardship programs have been shown to
enhance judicious antibacterial prescribing practices, improve
clinical outcomes, and reduce healthcare costs.3 Antifungal
stewardship can be effective by optimizing therapy and
decreasing unnecessary use resulting in cost savings.10
Currently, the available antifungal and antiviral therapies are
limited, making stewardship critically important, as efforts to
avoid the development of drug resistance and unnecessary

adverse drug effects are needed. Invasive fungal and viral
infections in the immunocompromised host can be devastating,
resulting in high rates of morbidity and mortality. Selecting the
most effective therapeutic agent, optimizing therapeutic dosing,
and using therapeutic drug monitoring when available are all
potentially effective points for stewardship interventions in this
vulnerable population.
Our study has limitations. This study was limited to freestanding children’s hospitals and may not be generalizable to
other clinical settings. We were unable to discriminate between
treatment and prophylaxis, and we did not assess appropriateness of use. Antifungals and antivirals were determined
using charge data, not medication administration information.
Nonetheless, antifungal and antiviral use varied broadly across
hospitals, even when comparing use in similar, high-risk
patients. Benchmarking antifungal and antiviral is an important
step in identifying targeted stewardship strategies to enhance
judicious antimicrobial prescribing.
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